Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taroh Satoh

Showing results (51-60 of 277) with videos related to

Pageof 28
Sort By:
Annals of Surgical Oncology|January 15, 2025
Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2018
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label studyKensei Yamaguchi, Kazumasa Fujitani, Fumio Nagashima, et al.
International Journal of Oncology|January 19, 2018
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cellsKosuke Taketo, Masamitsu Konno, Ayumu Asai, et al.
Medical Oncology (Northwood, London, England)|December 19, 2024
Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303)Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, et al.
International Journal of Molecular Sciences|April 17, 2025
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA VaccinesSikun Meng, Tomoaki Hara, Yutaka Miura, et al.
Cancer Science|February 26, 2019
Mitochondrial pyruvate carrier 1 expression controls cancer epithelial-mesenchymal transition and radioresistanceYuji Takaoka, Masamitsu Konno, Jun Koseki, et al.
Annals of Surgical Oncology|August 28, 2019
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal CancerTakaomi Hagi, Tomoki Makino, Makoto Yamasaki, et al.
Oncology Letters|June 29, 2012
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility studyTakenori Takahata, Jugoh Itoh, Taroh Satoh, et al.
Scientific Reports|July 4, 2023
Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resectionChihiro Sato, Hisato Kawakami, Ryo Tanaka, et al.
World Journal of Gastrointestinal Oncology|September 28, 2019
Gallbladder cancer harboring <i>ERBB2</i> mutation on the primary and metastatic site: A case reportChiaki Inagaki, Daichi Maeda, Akie Kimura, et al.
Pageof 28

Showing results (51-60 of 277) with videos related to

Sort By:
Pageof 28
Annals of Surgical Oncology|January 15, 2025
Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S-1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 7, 2018
Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label studyKensei Yamaguchi, Kazumasa Fujitani, Fumio Nagashima, et al.
International Journal of Oncology|January 19, 2018
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cellsKosuke Taketo, Masamitsu Konno, Ayumu Asai, et al.
Medical Oncology (Northwood, London, England)|December 19, 2024
Phase I study of neoadjuvant chemoradiotherapy with S-1 for clinically resectable type 4 or large type 3 gastric cancer in elderly patients aged 75 years and older (OGSG1303)Masayuki Shinkai, Motohiro Imano, Masaki Yokokawa, et al.
International Journal of Molecular Sciences|April 17, 2025
In Vivo Engineered CAR-T Cell Therapy: Lessons Built from COVID-19 mRNA VaccinesSikun Meng, Tomoaki Hara, Yutaka Miura, et al.
Cancer Science|February 26, 2019
Mitochondrial pyruvate carrier 1 expression controls cancer epithelial-mesenchymal transition and radioresistanceYuji Takaoka, Masamitsu Konno, Jun Koseki, et al.
Annals of Surgical Oncology|August 28, 2019
Dysphagia Score as a Predictor of Adverse Events Due to Triplet Chemotherapy and Oncological Outcomes in 434 Consecutive Patients with Esophageal CancerTakaomi Hagi, Tomoki Makino, Makoto Yamasaki, et al.
Oncology Letters|June 29, 2012
Sequential irinotecan hydrochloride/S-1 for S-1-resistant inoperable gastric cancer: A feasibility studyTakenori Takahata, Jugoh Itoh, Taroh Satoh, et al.
Scientific Reports|July 4, 2023
Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resectionChihiro Sato, Hisato Kawakami, Ryo Tanaka, et al.
World Journal of Gastrointestinal Oncology|September 28, 2019
Gallbladder cancer harboring <i>ERBB2</i> mutation on the primary and metastatic site: A case reportChiaki Inagaki, Daichi Maeda, Akie Kimura, et al.
Pageof 28